After obesity, GLP-1 research focused on Alzheimer’s… hypothesis centres on its ability to reduce inflammation in the brain… this is different from current approaches
Context Danish scientist Lotte Bjerre Knudsen, co-inventor of the first long-acting GLP-1 receptor agonist for treating type-2 diabetes and obesity, shared insights on ongoing research exploring GLP-1’s potential in addressing Alzheimer’s disease. The research focuses on the hypothesis that GLP-1 can reduce brain inflammation, offering a different therapeutic approach compared to existing Alzheimer’s treatments. Background…